Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium cromoglycate is a synthetic small molecule medication classified as a mast cell stabilizer. It is primarily used for the prophylactic treatment of asthma and allergic conditions such as allergic rhinitis and conjunctivitis. Additionally, it is administered orally to manage systemic mastocytosis and ulcerative colitis. The drug works by inhibiting the degranulation of sensitized mast cells, thereby preventing the release of histamine and other mediators involved in type I allergic reactions. Its mechanism may also involve inhibition of calcium influx into mast cells and possible modulation via G protein-coupled receptor 35 (GPR35). Sodium cromoglycate does not relieve acute asthma attacks but reduces their frequency and severity when used regularly[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium cromoglycate.